Editorial: Lutetium-177 labeled therapeutics:177Lu-PSMA is set to redefine prostate cancer treatment

Current Radiopharmaceuticals

Volumn 9, Issue 1, 2016, Pages 6-7

  Pillai, Ambikalmajan M R ^a   Russ Knapp, Furn F ^b  

^a Molecular Group of Companies   (India)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOTATATE LU 177; IODINE 131; LUTETIUM 177; MEDRONATE TECHNETIUM TC 99M; OCTREOTIDE LU 177; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; PROSTATE SPECIFIC MEMBRANE ANTIGEN LU 177; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; LUTETIUM; MEMBRANE ANTIGEN;

BONE METASTASIS; CANCER CELL; CANCER PATIENT; CAUSE OF DEATH; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; EDITORIAL; HUMAN; ISOTOPE LABELING; MOLECULAR WEIGHT; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGIST; PAROTID GLAND; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; RADIOISOTOPE THERAPY; THYROID CANCER; MALE; PROSTATIC NEOPLASMS;

ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LUTETIUM; MALE; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 84949801774     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/187447100901151123124826     Document Type: Editorial

References (6)

1. Knapp, F.F.; Pillai, M.R.A. Guest Editors, Thematic Issue: Luteteium-177 Labeled Therapeutics: Emerging Importance for Cancer Treatment and Therapy of Chronic Disease. Curr. Radiopharm. 2015, 8(2), pp. 77-159.
2. Banerjee, S.; Pillai, M.R.A.; Knapp, F.F. Jr. Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry and Practical Applications. Chem. Rev., 2015, 115, 2934-2974.
3. Oromieh, A.A.; Malcher, A.; Eder, M.; Eisenhut, M.; Linhart, H.G; Hadaschik, B.A. PET imaging with a [68Ga]gallium labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging., 2013, 40, 486-495.
4. Kratochwil, C.; Giesel, FL.; Eder M.; Oromieh, A.A.; Benešová, M.; Mier, W. [177Lu]Lutetium labelled PSMA ligand induced remission in a patient with metastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imaging., 2015, 42, 987-988.
5. Ahmadzadehfar, H.; Rahbar, K.; Kürpig, S.; Bögemann, M.; Claesener, M.; Eppard, E.; Gärtner, F.; Rogenhofer, S.; Schäfers, M.; Essler, M. Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. Eur. J. Nucl. Med. Mol. Imaging. Res., 2015, 5(1), 114. [Epub ahead of print].
6. Kabasakal, L.; Abu Qbeitah, M.; Aygün, A.; Yeyin, N.; Ocak, M.; Demirci, E.; Toklu, T. Pretherapeutic dosimetry of normal organs and tissues of 177Lu-PMSA-617 prostate specific membrane antigen (PSMA) inhibitor in patients with castration resistant prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2015. [Epub ahead of print].